Pheast Therapeutics
$24.6M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Pheast Therapeutics is currently valued at $154.6M as of October 15, 2025. The company has raised a total of $100.6M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.54x, Pheast Therapeutics has achieved a valuation that is 1.54 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Pheast Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Pheast Therapeutics Worth in 2025?
As of 2025, Pheast Therapeutics is valued at $154.6M, based on the company's Early Stage VC funding round in October 15, 2025. This valuation positions Pheast Therapeutics as one of the leading private companies in the sector.
Pheast Therapeutics Valuation History
Pheast Therapeutics's funding history demonstrates steady growth and investor confidence.
How Pheast Therapeutics Valuation is Determined
Private company valuations like Pheast Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Pheast Therapeutics Valuation FAQs
Is Pheast Therapeutics profitable?
Pheast Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Pheast Therapeutics's valuation compare to competitors?
Pheast Therapeutics is valued at $154.6M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Pheast Therapeutics IPO?
Pheast Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Pheast Therapeutics shares through secondary market platforms.